Biotech entity
All 3 tracked stories fall under one category: pharma. ANVISA is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. Each story carries 2.7 original sources on average, compared with 3.4 for the broader beat in this window.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 34 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: pharma. ANVISA is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. Each story carries 2.7 original sources on average, compared with 3.4 for the broader beat in this window. The 31-day window averages about 0.7 stories each week. Their average consequence score of 6 runs below the beat's 6.1 for that window. This profile follows 3 Biotech stories mentioning CDSCO across the period from February 22, 2026 to March 24, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 396 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CDSCO. Shared-story counts are live from our verified record — not editorial picks.
Government expands Production Linked Incentives for high-end medical hardware.
Department of Commerce holds strategic session to strengthen the export ecosystem.
Formal Announcement
Official confirmation of the bilateral agreement to strengthen medical product regulation.
MoU Exchange Initiated
Initial diplomatic exchange of the regulatory cooperation framework in New Delhi.
National Medical Device Policy
Union Cabinet approves policy to facilitate orderly growth of the medical device sector.
Indian health authorities have issued a formal warning regarding the rising misuse and health risks associated with affordable, non-regulated weight-loss injections. The move signals a tightening of oversight as the global demand for GLP-1 therapies triggers a surge in local compounding and unauthorized distribution.
The Indian Department of Commerce has convened a high-level Chintan Shivir to overhaul the nation's medical device export ecosystem. The initiative seeks to streamline regulatory frameworks and position India as a primary global manufacturing hub for high-end medical technology.
India and Brazil have formalized a Memorandum of Understanding (MoU) to harmonize regulatory standards for pharmaceutical and medical products. This bilateral agreement aims to streamline market access and enhance technical cooperation between two of the world's most influential emerging healthcare markets.
CDSCO is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
